Isolation of non-tuberculous mycobacteria among tuberculosis patients, a study from a tertiary care hospital in Lahore, Pakistan

Table 3 Clinical features, drug susceptibility and treatment outcome for a subgroup of 12 female patients with non-tuberculous mycobacterial disease

Pat/N	Age (years)	Site	symptoms	CXR- Finding	Co-morbidities	NTM-specie	DST Profile	TM Regimen	Follow-up AFB smears and cultures					TM duration	TM outcome
Pat/N	Age (years)	Site	symptoms	CXR- Finding	Co-morbidities	NTM-specie	DST Profile	TM Regimen	2 M	4 M	6 M	9 M	End of TM	TM duration	TM outcome
1	20	Pul	F, WL, PC, CP	BL/FCD	None	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
2	50	Pul	F, WL, PC, HM	BL/FCD	CLD, DM	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
3	64	Pul	F, WL, PC	BL/FCD	DM	MAC	CLR, MXF, AMK,LZD	EHR, CLR AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
4	48	Pul	F, HM, SOB	LT/FCD	None	MAC	CLR, MXF *AMK(r)*^a	EHR, CLR,	P/P	NA	NA	N/NG	N/NG	18 M	Cured
5	45	Pul	F, WL, PC	BL/FCD	CLD, DM	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
6	45	Pul	F, WL, PC	BL/FCD	CLD	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
7	54	Pul	F, WL, PC, HM	BL/FCD	DM	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
8	65	Pul	F, WL, PC	BL/FCD	DM	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured
9	68	Pul/ LN	F, WL, PC	BL/FCD	HCV+	MAC	CLR, MXF, AMK	EHR, CLR, AMK (6 M)	P/P	N/NG	N/NG	N/NG	N/NG	18 M	Cured
10	18	Pul	F, WL, PC	BL/FCD LT/PTX	None	M. abscessus	MXF, LZD, CLR	EHR+ CLR (6 M)-shifted to MXF+ LZD (3 M)	P/P	P/P	P/P	Expired	–	8 M	Died
11	65	Pul	F, PC	BL/FCD	None	M. abscessus	MXF, LZD, CLR	LZD, MXF AMK (3 M)	P/P	P/P	P/P	N/P	NA	12 M	LTFUP
12	32	Pul	F, WL, PC	LT/FCD	None	M. abscessus	MXF, LZD, CLR	MXF, LZD CLR (2 M)	P/P	P/P	N/NG	N/NG	N/NG	18 M	Cured

Pat patient, N number, CXR chest X-ray, NTM Non-tuberculous mycobacteria, DST Drug susceptibility testing, TM treatment, M month, Pul pulmonary, LN Lymph node, F Fever, WL Weight loss, PC Productive cough, CP Chest pain, SOB Shortness of breath, HM Hemoptysis, BL Bilateral, FCD Fibro-cavitary disease, LT Left, PTX Pneumothorax, CLD Chronic liver disease, DM Diabetes mellitus, HCV Hepatitis C virus, MAC Mycobacterium avium complex, CLR Clarithromycin, MXF Moxifloxacin, AMK Amikacin, LZD Linezolid, EHR Ethambutol + isoniazid + rifampicin, r Resistant, ^aresistant to amikacin (patient-4). P Positive, N Negative, NG No growth, NA Not available, LTFUP Lost to follow-up